BRPI0414527A - tratamento de tumores estromáticos gastrointestinais com imatinib e midostaurina - Google Patents

tratamento de tumores estromáticos gastrointestinais com imatinib e midostaurina

Info

Publication number
BRPI0414527A
BRPI0414527A BRPI0414527-5A BRPI0414527A BRPI0414527A BR PI0414527 A BRPI0414527 A BR PI0414527A BR PI0414527 A BRPI0414527 A BR PI0414527A BR PI0414527 A BRPI0414527 A BR PI0414527A
Authority
BR
Brazil
Prior art keywords
imatinib
midostaurin
treatment
gastrointestinal stromal
stromal tumors
Prior art date
Application number
BRPI0414527-5A
Other languages
English (en)
Inventor
Sasa Dimitrijevic
Jonathan A Fletcher
Sandra Leta Silberman
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0414527A publication Critical patent/BRPI0414527A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"TRATAMENTO DE TUMORES ESTROMáTICOS GASTROINTESTINAIS COM IMATINIB E MIDOSTAURINA". A presente invenção refere-se ao uso de uma combinação que compreende (a) imatinib ou um sal farmaceuticamente aceitável do mesmo e midostaurina ou um sal farmaceuticamente aceitável do mesmo para a preparação de um medicamento para o tratamento de tumores estromáticos gastrointestinais, como por exemplo tumores estromáticos gastrointestinais resistentes ao imatinib.
BRPI0414527-5A 2003-09-19 2004-09-17 tratamento de tumores estromáticos gastrointestinais com imatinib e midostaurina BRPI0414527A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50424503P 2003-09-19 2003-09-19
PCT/EP2004/010467 WO2005027971A1 (en) 2003-09-19 2004-09-17 Treatment of gastrointestinal stromal tumors with imatinib and midostaurin

Publications (1)

Publication Number Publication Date
BRPI0414527A true BRPI0414527A (pt) 2006-11-07

Family

ID=34375467

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414527-5A BRPI0414527A (pt) 2003-09-19 2004-09-17 tratamento de tumores estromáticos gastrointestinais com imatinib e midostaurina

Country Status (11)

Country Link
US (1) US20080096864A1 (pt)
EP (1) EP1667719B1 (pt)
JP (1) JP2007505859A (pt)
CN (1) CN100467064C (pt)
AT (1) ATE489109T1 (pt)
AU (1) AU2004273605B2 (pt)
BR (1) BRPI0414527A (pt)
CA (1) CA2538523A1 (pt)
DE (1) DE602004030265D1 (pt)
MX (1) MXPA06003056A (pt)
WO (1) WO2005027971A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0416680A (pt) * 2003-11-18 2007-02-13 Novartis Ag inibidores da forma mutante de kit
US20090075972A1 (en) * 2004-08-31 2009-03-19 Jan Cools Use of Midostaurin for Treating Gastrointestinal Stromal Tumors
PT1879585E (pt) * 2005-05-02 2013-07-23 Novartis Ag Utilização de derivados de pirimidilaminobenzamida para o tratamento de mastocitose sistémica
CA2615598C (en) * 2005-07-20 2014-04-15 Peter Valent Compositions for treatment of systemic mastocytosis
RU2443421C2 (ru) * 2005-11-14 2012-02-27 Университэт Цюрих Производные стауроспорина для применения при лечении альвеолярной рабдомиосаркомы

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
ITMI992711A1 (it) * 1999-12-27 2001-06-27 Novartis Ag Composti organici
DE60118430T2 (de) * 2000-10-27 2006-10-26 Novartis Ag Behandlung von gastrointestinalen stromatumoren
CN1326577C (zh) * 2002-02-28 2007-07-18 诺瓦提斯公司 N－{5－[4－(4－甲基－哌嗪－1－基甲基)－苯甲酰氨基]－2－甲基苯基}－4－(3－吡啶基)－2－嘧啶－胺涂层的支架
AU2003216621A1 (en) * 2002-04-10 2003-10-20 The Government Of The United States The Department Of Veterans Affairs Combination of glivec(sti571) with a cyclin-dependent kinase inhibitor, especially flavopiridol in the treatment of cancer

Also Published As

Publication number Publication date
EP1667719B1 (en) 2010-11-24
AU2004273605A1 (en) 2005-03-31
DE602004030265D1 (de) 2011-01-05
MXPA06003056A (es) 2006-05-31
AU2004273605B2 (en) 2008-07-31
CA2538523A1 (en) 2005-03-31
CN100467064C (zh) 2009-03-11
EP1667719A1 (en) 2006-06-14
WO2005027971A1 (en) 2005-03-31
JP2007505859A (ja) 2007-03-15
US20080096864A1 (en) 2008-04-24
ATE489109T1 (de) 2010-12-15
CN1852738A (zh) 2006-10-25

Similar Documents

Publication Publication Date Title
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
BRPI0007487B8 (pt) difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase
BRPI0410418A (pt) fenil quinolinas e seu uso como moduladores do receptor de estrogênio
CL2004001069A1 (es) Compuestos derivados de 1-benzoil-isoquinolinas sustituidos; procedimiento de preparacion, composicion farmaceutica; y uso para el tratamiento o profilaxis de diabetes tipo ii.
BR0312573A (pt) Derivados de fenil-[4-(3-fenil-1h-pirazol-4-il)-pirimidin-2-il]-amina
CL2007001427A1 (es) Sal de maleato de 5-amino-3-(2',3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d]pirimidin-2-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una infeccion po
BRPI0418099A (pt) compostos, composição farmacêutica, e uso de um composto
TN2009000180A1 (en) NOVEL 1,4-BENZOTHIEPIN-l,1-DIOXIDE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL GROUPS, METHOD FOR PRODUCING DRUGS CONTAINING SAID COMPOUNDS AND USE THEREOF
ECSP088283A (es) Compuestos de piridina 5- (fenilisoxazoliletoxi) -triazol- 3-ilo substituidos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
CL2008001932A1 (es) Compuestos derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b]piridazina, inhibidores de cq1epsilon y/o ck1delta; procedimiento de preparacion; composicion farmaceutica que los comprende; y uso en el tratamiento de desordenes del sueno, trastorno del ritmo circadiano, cancer y enfermedad de alzheimer.
UY28931A1 (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
PT1696905E (pt) 2-aminotetralinas substituídas para o tratamento preventivo da doença de parkinson
SV1999000194A (es) Preparado farmaceuticio de moxifloxacina ref. lea 33327-sv
CR10305A (es) "derivados sustituidos de cromanol y su uso.
CL2008001820A1 (es) Compuestos derivados de aril-isoxasol-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y uso en la preparacion de medicamentos utiles en el tratamiento de trastornos cognitivos y enfermedades relacionadas con alzheimer.
BR0113590A (pt) 7-oxo-piridopirimidinas
BR0213684A (pt) Uso de antagonistas do receptor de endotelina para o tratamento de doenças tumorìgenas
GT200800066A (es) Derivados de 9-cloro-15-deoxiprostaglandina, procedimiento para su preparacion y su uso como medicamento.
UA106200C2 (uk) Заміщені похідні оксіндолу та їхнє застосування для лікування захворювань, залежних від вазопресину
CL2008001719A1 (es) Compuestos derivados de [1,10]-fenantrolina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades neurodegenerativas o hematologicas.
BR0309878A (pt) Heterotriciclil-6-alquilideno-penemas como inibidores de beta-lactamase
BRPI0414527A (pt) tratamento de tumores estromáticos gastrointestinais com imatinib e midostaurina
GT200600106A (es) Agentes endoparasiticidas
TW200501946A (en) Pharmaceutical composition for the treatment of schizophrenia in a patient with overweight
CL2007003281A1 (es) Compuesto 1-(4-metilfenil)dihidro-1h-pirrolo[1,2-a]imidazol-2,5-(3h,6h)-diona; composicion farmaceutica; y uso para el tratamiento terapeutico o preventivo de la neurotoxicidad periferica inducida por quimioterapeuticos.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2167 DE 17/07/2012.